Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma

NCT07689175 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma (HCC)

Interventions

DRUG: Nivolumab
DRUG: Ipilimumab (3 mg/kg)

Sponsor

University of Texas Southwestern Medical Center

Collaborators

[object Object]